2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-E70127
    Serratiopeptidase
    		Inhibitor
    Serratiopeptidase is an anti-inflammatory agent. Serratiopeptidase has anti-inflammatory, anti-biofilm, mucolytic, fibrinolytic, and wound-healing properties. Serratiopeptidase can be used for combat COVID-19-induced respiratory syndrome research.
    Serratiopeptidase
  • HY-100304A
    KW-8232
    		Inhibitor 98.10%
    KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232
  • HY-135867F
    NHC-diphosphate triammonium
    		Inhibitor 98.80%
    NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
    NHC-diphosphate triammonium
  • HY-155488
    SHEN26
    		99.10%
    SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19).
    SHEN26
  • HY-W039454
    2,4-Dichlorobenzyl alcohol
    		99.40%
    2,4-Dichlorobenzyl alcohol is an orally active mild antiseptic, with a broad spectrum for bacterial and virus associated with mouth and throat infections. 2,4-Dichlorobenzyl alcohol exhibits prenatal developmental toxicity.2,4-Dichlorobenzyl alcohol can be used in the study of SARS-CoV.
    2,4-Dichlorobenzyl alcohol
  • HY-145592
    Ruzotolimod
    		99.92%
    Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2.
    Ruzotolimod
  • HY-B0260S4
    Methylprednisolone-d2
    		Inhibitor 99.11%
    Methylprednisolone-d2 is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
    Methylprednisolone-d<sub>2</sub>
  • HY-113225S3
    Guanosine triphosphate-15N5 dilithium
    Guanosine triphosphate-15N5 (GTP-15N5) dilithium is 15N labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.
    Guanosine triphosphate-<sup>15</sup>N<sub>5</sub> dilithium
  • HY-149321
    SARS-CoV-2 nsp14-IN-3
    		Inhibitor
    SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 3.5 μM).
    SARS-CoV-2 nsp14-IN-3
  • HY-124304
    Pinokalant
    		Inhibitor 99.09%
    Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity.
    Pinokalant
  • HY-P4388
    Z-Arg-Leu-Arg-Gly-Gly-AMC
    		99.93%
    Z-Arg-Leu-Arg-Gly-Gly-AMC is a peptide substrate of SARS-CoV PLpro.
    Z-Arg-Leu-Arg-Gly-Gly-AMC
  • HY-139442
    RdRP-IN-2
    		Inhibitor 98.01%
    RdRP-IN-2 is a RNA dependent RNA polymerase (RdRp) inhibitor. RdRP-IN-2 significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 μM.RdRP-IN-2 also inhibits Feline coronavirus (FIPV) replication.
    RdRP-IN-2
  • HY-N10109A
    Gallinamide A TFA
    		Inhibitor 99.85%
    Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC50: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC50: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC50: 50 nM).
    Gallinamide A TFA
  • HY-155144
    CDD-1845
    		Inhibitor 99.60%
    CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a Ki of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants.
    CDD-1845
  • HY-126419
    Kobophenol A
    		Inhibitor 99.90%
    Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC50 of 1.81 μM and inhibits SARS-CoV-2 viral infection in cells with an EC50 of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC50 of 52 µM.
    Kobophenol A
  • HY-P99947
    Rimteravimab
    		Inhibitor ≥99%
    Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2.
    Rimteravimab
  • HY-136284
    XP-59
    		Inhibitor 99.67%
    XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM.
    XP-59
  • HY-144800
    FWM-1
    		Inhibitor
    FWM-1 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor with binding free energy equals -328.6 kcal/mol. FWM-1 effectively disrupts the binding of ATP to the SARS-COV2 helicase enzyme.
    FWM-1
  • HY-B0260S3
    Methylprednisolone-d7
    		Inhibitor 99.73%
    Methylprednisolone-d7 is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
    Methylprednisolone-d<sub>7</sub>
  • HY-138208
    Z-Phe-Tyr(tBu)-diazomethylketone
    		Inhibitor ≥99.0%
    Z-Phe-Tyr(tBu)-diazomethylketone is a potent cathepsin L inhibitor. Z-Phe-Tyr(tBu)-diazomethylketone mediates reovirus disassembly. Z-Phe-Tyr(tBu)-diazomethylketone decreases viral detection.
    Z-Phe-Tyr(tBu)-diazomethylketone
Cat. No. Product Name / Synonyms Species Source